Capricor Therapeutics (NASDAQ:CAPR) Trading 16.4% Higher on Analyst Upgrade

Capricor Therapeutics, Inc. (NASDAQ:CAPR) rose 16.4% during mid-day trading on Wednesday after Oppenheimer upgraded the stock from a market perform rating to an outperform rating. The stock traded as high as $9.15 and last traded at $9.6510. 1,782,658 shares traded hands during trading, a decline of 39% from the average session volume of 2,898,896 shares. The stock had previously closed at $8.29.

Several other equities research analysts also recently weighed in on CAPR. Maxim Group downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Roth Capital downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research note on Monday, July 27th. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Piper Sandler downgraded Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 target price for the company. in a research note on Thursday, July 30th. Finally, Cantor Fitzgerald upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Capricor Therapeutics has an average rating of “Hold” and a consensus price target of $29.15.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 25,000 shares of company stock valued at $759,158. 9.20% of the stock is currently owned by corporate insiders.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: The FDA extended the PDUFA target action date for deramiocel by three months, to November 22, 2026, after Capricor submitted additional Phase 3 HOPE-3 data and analyses. The extension is not a rejection and gives the company more time to address FDA questions and support its proposed indication. Capricor FDA review extension
• Positive Sentiment: Oppenheimer upgraded CAPR from “market perform” to “outperform,” citing increased optimism that deramiocel could ultimately receive approval. The upgrade provides some support after the stock’s substantial selloff. Oppenheimer upgrade
• Neutral Sentiment: Reported call-option volume was approximately 190% above typical levels, suggesting speculative bullish positioning, although options activity does not confirm a sustained recovery. Reported short-interest data showed zero shares and therefore offers no meaningful short-squeeze signal.
• Negative Sentiment: Multiple law firms announced or promoted securities-fraud class actions covering investors who purchased CAPR shares from December 17, 2025, through July 26, 2026. The lawsuits allege that Capricor and executives made misleading statements or omissions regarding deramiocel’s approval pathway, statistical analysis plan, FDA compliance and clinical-data integrity; the lead-plaintiff deadline is September 28, 2026. Capricor securities class action
• Negative Sentiment: Reports tied the selloff to FDA briefing materials that allegedly revealed unagreed changes to the HOPE-3 statistical analysis plan and raised questions about data integrity. The company’s recent earnings call also reportedly omitted analyst Q&A, adding to investor uncertainty. Capricor data-integrity concerns

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. Walleye Capital LLC acquired a new position in Capricor Therapeutics in the first quarter valued at about $5,397,000. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth $1,039,000. Bank of America Corp DE grew its holdings in shares of Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after buying an additional 361,664 shares during the period. Moody Aldrich Partners LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at $6,025,000. Finally, UBS Group AG lifted its holdings in Capricor Therapeutics by 91.0% during the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock worth $6,875,000 after acquiring an additional 113,499 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

The business has a 50 day simple moving average of $15.57 and a 200-day simple moving average of $24.61. The stock has a market capitalization of $558.83 million, a price-to-earnings ratio of -3.86 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, equities analysts predict that Capricor Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.